Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 164 participants.

Also called NCT07616544

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 164 participants (planned count) (from the registry)
Sponsor
Liu Qiang (from the registry)
Registry
  • NCT NCT07616544
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07616544. Randomized; triple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization
Intervention (Drug)
Qidan Xiaoke Granules + Standard Medical Therapy
Intervention (Drug)
Placebo + Standard Medical Therapy
Lead sponsor
Liu Qiang (class: other)

Record details

Record id
cardio:ct-nct07616544
Content hash
447f78e5557a643584188324e6dc1071acc60901bd846b2314d05c3c1d0f73a3